Encyclopedia of AIDS

Living Edition
| Editors: Thomas J. Hope, Douglas Richman, Mario Stevenson

Antiretroviral Therapy for HIV-Infected Infants, Children, and Adolescents in Resource-Rich Settings

  • Sima S. Toussi
  • Michael Rosenberg
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9610-6_448-1

Definition

The treatment of HIV-infected infants, children, and adolescents (ICA) mandates the use of a combination of antiretroviral drugs (ARVs) from two or more classes targeting different steps in the HIV life cycle. These classes include nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand-transfer inhibitor (INSTI), and attachment/entry inhibitors. There are now 21 Food and Drug Administration (FDA) approved therapeutic agents available for pediatric and adolescent populations ≤17 years of age, with several of those medications available in child-friendly formulations such as suspensions, chewable tablets, and powders. In qualifying adolescents, the use of multiple ARVs combined into a single tablet, also known as single tablet regimens (STRs), may also be considered. The goals of combination antiretroviral therapy (cART), recommendations of when and why to initiate therapy, an...

Keywords

Virologic Failure Tanner Stage Pediatric Clinical Trial Drug Resistance Testing Single Tablet Regimen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Bain-Brickley D, Butler LM, Kennedy GE, Rutherford GW. Interventions to improve adherence to antiretroviral therapy in children with HIV infection. Cochrane Database Syst Rev. 2011;(Issue 12).Google Scholar
  2. Bamford A, Turkova A, Lyall H, Foster C, Klein N, Bastiaans D, Burger Dk, Bernadi S, Butler K, Chiappini E, Clayden P, Negra M, Giacomet V, Giaquinto C, Gibb D, Galli L, Hainaut M, Koros M, Marques L, Nastouli E, Niehues T, Noguera-Julian A, Rojo P, Rudin C, Scherpbier HJ, Tudor-Williams G, Welch SB. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. HIV Med. 2015;1–42.Google Scholar
  3. Brody S, Williams P, Seage GR, Oleske JM, Van Dyke R, McIntosh K, PACTG 219C Team. Antiretroviral treatment in pediatric HIV infection in the United States from clinical trials to clinical practice. JAMA. 2005;293(18):2213–20.CrossRefGoogle Scholar
  4. Campbell-Yesufu OT, Gandhi RT. Update on HIV-2 infection. CID. 2011;52(6):780–7.CrossRefGoogle Scholar
  5. FDA New Pediatric Labeling Information Database. 2015. http://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase. Accessed 2 Aug 2015
  6. HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS. 2006;20(9):1289–94.CrossRefGoogle Scholar
  7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 2015a. https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 11 Aug 2015.
  8. Panel on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the use of Antiretroviral Agents in Pediatric HIV infection. 2015b. https://aidsinfo.nih.gov/contentfiles/lvguidelines/PediatricGuidelines.pdf. Accessed 29 July 2015.
  9. Peacock-Villada E, Richardson BA, John-Stewart GC. Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries. Pediatrics. 2011;127(2):e423–41.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E. Optimisation of antiretroviral therapy in HIV infected children under 3 years of age. Cochrane Database of Systematic Reviews. 2014;(Issue 5).Google Scholar
  11. Persaud D, Gay H, Ziemniack C, Chen Y, Piatak M, Chun TW, Strain M, Richman D, Luzuriaga K. Absence of detectable HIV-1 viremia after treatment cessation in an infant. New Eng J Med. 2013;369(19):1828–35.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Selik RM, Mokotoff ED, Branson B, Owen MS, Whitmore S, Hall HI. Revised surveillance case definition for HIV infection – United States, 2014. MMWR. 2014;63(3):1–10.Google Scholar
  13. United Nations World Economic Situation and Prospects, 2015; http://www.un.org/en/development/desa/policy/wesp/wesp_archive/2015wesp_full_en.pdf. Accessed 26 July 2015.
  14. Van der Linden D, Callens S, Brichard B, Colebunders R. Pediatric HIV: new opportunities to treat children. Expert Opin Pharmacother. 2009;10(11):1783–91.CrossRefPubMedGoogle Scholar
  15. Violari A, Cotton M, Gibb D, Babiker A, Steyn J, Madhi S, Jean-Philippe J, McIntyre J. Early antiretroviral therapy and mortality among HIV-infected infants. New Eng J Med. 2008;359:2233–44.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Division of Pediatric Infectious Diseases, Department of PediatricsNY Presbyterian Hospital – Weill Cornell Medical CollegeNew YorkUSA
  2. 2.Division of Pediatric Infectious DiseasesJacobi Medical Center, Albert Einstein College of Medicine, Yeshiva UniversityBronxUSA